関節リウマチ治療薬の世界市場:DMARD、NSAID、コルチコステロイド、鎮痛薬...市場調査レポートについてご紹介

【英文タイトル】Global Rhematoid Arthritis Drugs Market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding RA
• Etiology and pathophysiology
• Signs and symptoms
• Diagnosis
• Disease management
• Economic burden of RA
• Epidemiology

PART 06: Impact of biologics in RA

PART 07: Pipeline portfolio
• Novel mechanisms targeted by pipeline candidates
• Clinical trials for RA

PART 08: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 09: Market segmentation by drug class
• DMARDs
• NSAIDs
• Corticosteroids
• Analgesics
• Others
• Global DMARDs market
• Global NSAIDs market
• Global corticosteroids market
• Global analgesics market

PART 10: Market segmentation by MOA
• TNF inhibitors
• IL-1 blockers
• JAK inhibitors
• Selective costimulation modulators

PART 11: Market segmentation by type of molecule
• Biologics
• Small molecules

PART 12: Market segmentation by ROA
• Oral
• Parenteral
• Topical

PART 13: Market segmentation by dosage form
• Solid
• Liquid
• Semi-solid

PART 14: Geographical segmentation
• RA drugs market in Americas
• RA drugs market in US
• RA drugs market in EMEA
• RA drugs market in Germany
• RA drugs market in UK
• RA drugs market in Spain
• RA drugs market in Italy
• RA drugs market in France
• Rheumatoid arthritis drugs market in APAC
• RA drugs market in Japan
• RA drugs market in Australia
• RA drugs market in India
• RA drugs market in China

PART 15: Key leading countries

PART 16: Market drivers
• Growing older population
• Market dominance of biologics
• Promising drug pipeline
• Changing lifestyle patterns
• Advances in diagnosis technology

PART 17: Impact of drivers

PART 18: Market challenges
• Increasing costs of biologicals
• Loss of patent exclusivity of branded therapies
• Use of complementary and alternative medicines (CAMs)
• Adverse effects of drugs
• Stringent regulations

PART 19: Impact of drivers and challenges

PART 20: Market trends
• Emergence of biosimilars
• Patient assistance programs
• Popularity of off-label and traditional treatment options
• Strategic alliances
• Increase in public awareness

PART 21: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• AbbVie
• Amgen
• BMS
• F. Hoffmann-La Roche
• Johnson & Johnson
• Pfizer
• Other prominent vendors

PART 22: Appendix4
• List of abbreviations4

PART 23: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for RA drugs
Exhibit 03: Classification of RA based on disease severity
Exhibit 04: Classification of RA based on disease severity 2016
Exhibit 05: Etiology and pathophysiology of RA
Exhibit 06: Signs and symptoms of RA
Exhibit 07: Diagnostic tests for RA
Exhibit 08: Treatment options for RA
Exhibit 09: Non-pharmacological therapies used for RA
Exhibit 10: Pharmacotherapy therapy for RA
Exhibit 11: Drugs used to treat RA
Exhibit 12: Classification of surgical treatment for RA
Exhibit 13: Percentage share of treatment of RA 2016
Exhibit 14: Historical milestones in treatment of RA
Exhibit 15: Treatment algorithm for RA
Exhibit 16: Economic burden of RA
Exhibit 17: Annual treatment costs of RA within Europe and US 2015 ($)
Exhibit 18: Cost difference between biological DMARDs and non-biological DMARDs
Exhibit 19: Projected prevalence of RA in Americas 2010-2030 ($ millions)
Exhibit 20: New cases of RA in UK per year 2016
Exhibit 21: Existing cases of RA in UK
Exhibit 22: Impact of biologics on various sectors
Exhibit 23: Pipeline molecules for RA
Exhibit 24: Novel targets of pipeline candidates
Exhibit 25: Candidates under development: Baricitinib
Exhibit 26: Candidates under development: Decernotinib
Exhibit 27: Candidates under development: CCX354
Exhibit 28: Candidates under development: Sirukumab
Exhibit 29: Candidates under development: Infliximab biosimilar
Exhibit 30: Candidates under development: Secukinumab
Exhibit 31: Candidates under development: Bimekizumab
Exhibit 32: Clinical trials of RA drugs by phase 2016
Exhibit 33: Clinical trials of RA drugs by status 2016
Exhibit 34: Global RA drugs market 2015-2020 ($ billions)
Exhibit 35: Opportunities in RA drugs industry
Exhibit 36: Five forces analysis
Exhibit 37: Global RA drugs market segmentation by drug class
Exhibit 38: Examples of non-biologic DMARDs and biologic DMARDs for RA
Exhibit 39: NSAIDs used to treat RA
Exhibit 40: Market share of global RA drugs market by drug class 2015
Exhibit 41: Global DMARDs market 2015-2020 ($ billions)
Exhibit 42: Global NSAIDs market 2015-2020 ($ billions)
Exhibit 43: Global corticosteroids market 2015-2020 ($ billions)
Exhibit 44: Global analgesics market 2015-2020 ($ billions)
Exhibit 45: Market segmentation of global RA drugs market by MOA
Exhibit 46: Mean percentage of patients receiving TNF inhibitors 2010 and 2015
Exhibit 47: Global RA drugs market share by MOA 2015
Exhibit 48: Global RA drugs market segmentation by type of molecule
Exhibit 49: Global RA drugs market share by type of molecules 2015
Exhibit 50: Global RA drugs market segmentation by ROA
Exhibit 51: Global RA drugs market segmentation by ROA 2015
Exhibit 52: Global RA drugs market segmentation by dosage form
Exhibit 53: Global RA drugs market segmentation by dosage form 2015
Exhibit 54: Global RA drugs by geography 2015
Exhibit 55: Global RA drugs market by geography 2015-2020 ($ billions)
Exhibit 56: Global RA drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 57: RA drugs market in Americas 2015-2020 ($ billions)
Exhibit 58: RA drugs market in Americas by country 2015
Exhibit 59: RA drugs market in US 2015-2020 ($ billions)
Exhibit 60: RA drugs sales in US by drug class 2015
Exhibit 61: Drivers and challenges of RA drugs market in US
Exhibit 62: RA drugs market in EMEA 2015-2020 ($ billions)
Exhibit 63: RA drugs market in EMEA by country 2015
Exhibit 64: RA sales in EMEA by drug class 2015
Exhibit 65: RA drugs market in Germany 2015-2020 ($ billions)
Exhibit 66: RA drugs market in UK 2015-2020 ($ billions)
Exhibit 67: RA drugs market in Spain 2015-2020 ($ millions)
Exhibit 68: RA drugs market in Italy 2015-2020 ($ millions)
Exhibit 69: RA drugs market in France 2015-2020 ($ millions)
Exhibit 70: RA drugs market in APAC 2015-2020 ($ billions)
Exhibit 71: RA drugs market in APAC by country 2015
Exhibit 72: RA drugs market in Japan 2015-2020 ($ billions)
Exhibit 73: RA drugs sales in Japan by drug class 2015
Exhibit 74: Drivers and challenges to growth of RA drugs market in Japan
Exhibit 75: RA drugs market in Australia 2015-2020 ($ millions)
Exhibit 76: RA drugs sales in Australia by drug class 2015
Exhibit 77: Drivers and challenges in RA drugs market in Australia
Exhibit 78: RA drugs market in India 2015-2020 ($ billions)
Exhibit 79: RA sales in India by drug class 2015
Exhibit 80: RA drugs market in China 2015-2020 ($ millions)
Exhibit 81: RA drugs sales in China by drug class 2015
Exhibit 82: Key leading countries
Exhibit 83: Population aged 60 years and over: World, developed and developing regions ($ millions)
Exhibit 84: FDA approval of biologicals
Exhibit 85: List of pipeline molecules
Exhibit 86: Lifestyle factors – Risk of rheumatoid arthritis
Exhibit 87: Impact of drivers
Exhibit 88: Average annual treatment cost of Humira, Enbrel, and Remicade 2014 ($)
Exhibit 89: Approval and patent expiries of top selling biologics
Exhibit 90: CAM therapies for RA
Exhibit 91: Usage of CAM in US
Exhibit 92: Side effects associated with RA
Exhibit 93: Impact of drivers and challenges
Exhibit 94: Patient assistance programs offered by companies
Exhibit 95: Revenue share of RA drugs by vendors 2015
Exhibit 96: YoY sales comparison of top drugs 2012-2014 ($ billions)
Exhibit 97: Competitive assessment of top RA drugs
Exhibit 98: Revenue share of RA drugs 2015
Exhibit 99: AbbVie: Product segmentation by revenue 2014
Exhibit 100: AbbVie: YoY revenue and growth rate of Humira 2012-2014 ($ billions)
Exhibit 101: AbbVie: YoY revenue and growth rate of Humira (in US) 2012-2014 ($ billions)
Exhibit 102: AbbVie: YoY revenue and growth rate of Humira (ROW) 2012-2014 ($ billions)
Exhibit 103: Sales of Humira in major markets
Exhibit 104: AbbVie: SWOT analysis
Exhibit 105: Amgen: YoY revenue and growth rate of Enbrel (in US and Canada) 2012-2014 ($ billions)
Exhibit 106: Amgen: YoY revenue and growth rate of Enbrel (in US) 2012-2014 ($ billions)
Exhibit 107: Amgen: YoY revenue and growth rate of Enbrel (in Canada) 2012-2014 ($ millions)
Exhibit 108: Amgen: SWOT analysis
Exhibit 109: BMS: Segmentation by revenue 20141
Exhibit 110: BMS: YoY revenue and growth rate of Orencia 2012-2014 ($ billions)
Exhibit 111: BMS: YoY revenue and growth rate of Orencia (in US) 2012-2014 ($ millions)
Exhibit 112: BMS: YoY revenue and growth rate of Orencia (ROW) 2012-2014 ($ millions)
Exhibit 113: Orencia sales for RA in major markets 2014
Exhibit 114: BMS: SWOT analysis
Exhibit 115: RA products by revenue 2014
Exhibit 116: F. Hoffmann-La Roche: YoY growth and revenue generated from product sales of MabThera/Rituxan 2011-2014 ($ billions)
Exhibit 117: MabThera/Rituxan geographic segmentation by revenue 2014
Exhibit 118: F.Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2012-2014 ($ millions)
Exhibit 119: Actemra/RoActemra geographic segmentation by revenue 2014
Exhibit 120: F. Hoffmann-La Roche: SWOT analysis
Exhibit 121: Johnson & Johnson: Segmentation of key drugs 2014
Exhibit 122: Johnson & Johnson: YoY growth rate and revenue of Remicade 2012-2014 ($ billions)
Exhibit 123: Johnson & Johnson: YoY growth rate and revenue of Remicade (in US) 2012-2014 ($ billions)
Exhibit 124: Johnson & Johnson: YoY growth rate and revenue of Remicade (ROW) 2012-2014 ($ billions)
Exhibit 125: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2012-2014 ($ millions)
Exhibit 126: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (in US) 2012-2014 ($ millions)
Exhibit 127: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (ROW) 2012-2014 ($ millions)
Exhibit 128: Johnson & Johnson: SWOT analysis
Exhibit 129: Pfizer: Rhematoid drugs product segmentation by revenue 2014
Exhibit 130: Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2012-2014 ($ billions)
Exhibit 131: Pfizer: YoY revenue and growth rate of Celebrex 2012-2014 ($ billions)
Exhibit 132: Pfizer: YoY revenue and growth rate of Xeljanz 2012-2014 ($ billions)
Exhibit 133: Pfizer: SWOT analysis


【レポート販売概要】

■ タイトル:関節リウマチ治療薬の世界市場:DMARD、NSAID、コルチコステロイド、鎮痛薬
■ 英文:Global Rhematoid Arthritis Drugs Market 2016-2020
■ 発行日:2016年2月17日
■ 調査会社:Technavio
■ 商品コード:IRTNTR8751
■ 調査対象地域:グローバル
  • 菓子類加工機械の世界市場予測(~2023年)
    “Confectionery processing equipment market is projected to grow at a CAGR of 6.90%”The confectionery processing equipment market is estimated to be valued at USD 4.69 billion in 2018, and is projected to reach USD 6.55 billion by 2023, at a CAGR of 6.90% from 2018. Factors such as growth of the retail industry have driven the growth of the confectionery processing equipment market. Growth in deman …
  • MMOG(大規模マルチプレイヤーオンラインゲーム)のグローバル市場(2014-2018)
    About MMO Games MMO games or massively multiplayer online games refer to videogames that allow a large number of players to participate simultaneously over an internet connection. These games usually take place in a shared world that the gamer can access after purchasing or installing the game software. MMOs usually have at least one persistent world that continues to exist even after users have e …
  • 薬物乱用検査の世界市場2015
    During the next decade, the abused drug testing market will undergo significant transformation. These changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and cost per test are more critic …
  • 世界における電解質向け化学試薬の製品パイプライン動向2015
    Electrolyte Chemistry Reagents - Pipeline Review, 2015 Summary GlobalData's Medical Devices sector report, “Electrolyte Chemistry Reagents - Pipeline Review, 2015" provides an overview of Electrolyte Chemistry Reagents currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The r …
  • 世界のヘッドアップディスプレイ市場動向及び予測(2013 – 2020)
    Head-Up Display (HUD) system exhibits the information on the windshield of the vehicle operator enabling him to concentrate on driving without having to divert his attention from the windscreen. The technology provides safety and comfort to the drivers or pilots; technologically advanced systems even offer entertainments add-on with the whole HUD system. The HUD system makes vehicle operators well …
  • 2014年戦略提言:RSウイルスの診断検査市場
    The report presents a detailed analysis of the Respiratory Syncytial Virus diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Respiratory Syncytial Virus definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments:      …
  • 世界の地上光ネットワーク市場動向(2012-2016)
    TechNavio's analysts forecast the Global Terrestrial Optics market to grow at a CAGR of 4.81 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing rollout of fiber optics networks in China and Southeast Asia. The Global Terrestrial Optics market has also been witnessing the increasing price competition among terrestrial optical network equip …
  • メンブレン式ドライヤーの世界市場分析:製品別(多孔質、非多孔質)、用途別(食品・飲料、医療、産業、電子/半導体、通信)、セグメント予測、-2020
    The global membrane air dryers market is expected to reach USD 662.7 million by 2020. Apart from regular air purity requirements, special applications require high degree of air purification, particularly in the medical sector, which is expected to drive the membrane air dryers market. These products are increasingly being used in the medical sector, particularly dentistry. Membrane air dryers hel …
  • 不応性慢性リンパ性白血病:グローバル臨床試験レビュー(2014年上半期)
    Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014" provides data on the Refractory Chronic Lymphocytic Leukemia (CLL) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ref …
  • 歯科用注射器の世界市場予測(~2021)
    The global dental syringes market is projected to reach USD 126.9 Million by 2021 from USD 98.5 Million in 2016; growing at a CAGR of 5.2% during 2016-2021. The rising demand for dental syringes can be attributed to the growing technological advancements and growth in geriatric population. On the basis of product, the dental syringes market is categorized into three segments, namely, non-disposabl …
  • 世界のスマートウォッチ市場動向:Global Smartwatches Market 2014-2018
    TechNavio's analysts forecast the Global Smartwatches market to grow at a CAGR of 115.2 percent over the period 2014-2018. One of the key factors contributing to this market growth is the entrance of big vendors into the Global Smartwatches market. The Global Smartwatches market has also been witnessing an increase in R&D spending. However, the lack of proper technology standards could pose a chal …
  • ナチュラルフレグランスの世界市場予測(~2024年)
    “Increasing use of natural fragrance ingredients in various applications is expected to drive the natural fragrance market.” The natural fragrance market is estimated to grow from USD 2.7 billion in 2019 to USD 4.3 billion by 2024, at a CAGR of 9.6%. It is driven mainly by the increasing use of natural fragrance ingredients such as essential oils and natural extracts in various applications such a …
  • US Hospital Microbiology Testing Market 2014
    This new report from Venture Planning Group contains 997 pages, 87 tables, and presents a comprehensive analysis of the US hospital microbiology testing market, including: Major issues pertaining to the US hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Current scien …
  • 洗濯機の世界市場分析:製品別(全自動、半自動、乾燥機)、技術別(スマートコネクト、従来型)、容量別、エンドユーザー別、用途別、地域別、セグメント予測、2014-2025
    The global washing machine market is expected to reach USD 42.16 billion by 2025, according to a new report by Grand View Research, Inc. Increased needs for differentiated products and services have led to an upsurge in investments for R&D activities. Ongoing advancements, such as coin laundry, crowdsourced supply, and on-demand services, are drawing investors toward the laundromat and laundry ind …
  • データセンター液体冷却の世界市場予測:ラックベース液体冷却、列ベース液体冷却、単相浸漬式冷却法、二相浸漬式冷却法
    The Data center liquid cooling market is estimated to grow from USD 827.8 Million in 2016 to USD 2969.8 Million by 2021, at a high Compound Annual Growth Rate (CAGR) of 29.11% during the forecast period. Liquid cooling data center solutions are gaining a significant importance among organizations as they are scalable and universally designed. Liquid cooling data center concept uses mineral-based o …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。